Drug Profile
Tapentadol intranasal - Torrent Pharmaceuticals
Latest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Torrent Pharmaceuticals
- Class Amines; Opioid analgesics; Phenols; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 20 Apr 2022 Tapentadol intranasal is still in phase III for Postoperative pain in India
- 29 Oct 2019 Torrent Pharmaceuticals completes a phase III trial in Postoperative pain in India (Intranasal) (CTRI2019-03-018143)
- 01 Apr 2019 Phase-III clinical trials in Postoperative pain in India (Intranasal) (CTRI2019-03-018143)